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Approximately 8 million people worldwide are infected by the protozoan parasite
Trypanosoma cruzi, the causative agent of Chagas disease. After a latent period that
can last years or decades, 10% to 30% of infected people develop serious compli-
cations, such as cardiomyopathy or gastrointestinal dysfunction. Contrary to popular
belief, Chagas disease is not solely a vector-borne infection of Latin America.
Clinicians in nonendemic regions must be aware of the potential for childhood
T cruzi infections.
Humans typically acquire the parasite through contact with the infected feces
of blood-feeding triatomine insects. Vector-mediated transmission occurs in
endemic regions that extend from the southern United States to the southern
cone of South America. T cruzi can also be transmitted in food and beverages
contaminated with triatomine feces, via infected organ transplants and blood
transfusions, and vertically from mother to child. In the United States, human
contact with triatomines isminimal, and blood donations are screened for Tcruzi.
However, more than 300,000 US residents, mostly immigrants from Latin
America, may harbor chronic T cruzi infections. Many of those infected are
children and reproductive-age women.
Vertical transmission is an underrecognized problem. Children born to
infected mothers have an approximately 5% chance of acquiring the parasite.
Although there has been only one reported case of congenital Tcruzi infection in
the United States (in an infant born in 2010 to a Bolivian mother), several
hundred undetected congenital T cruzi infections are estimated to occur in the
United States each year. Diagnosis is difficult becausemost infected newborns are
asymptomatic. A minority of infected infants demonstrate nonspecific signs and
symptoms, including low Apgar scores, low birthweight, respiratory distress,
hepatosplenomegaly, anasarca, pericardial and pleural effusions, and meningo-
encephalitis. The presentation can easily be confused with neonatal sepsis or
TORCH infections (which include toxoplasmosis, rubella, cytomegalovirus, and
herpes viruses). Clinicians may overlook T cruzi in the differential diagnosis,
especially in nonendemic areas.
To improve detection of congenital infections, the World Health Organization
recommends antenatal T cruzi screening in all pregnant women who have ever
lived or received a blood transfusion in an endemic region. Infected women are
not treated prenatally to prevent vertical transmission because antitrypanosomal
medications are contraindicated during pregnancy and breastfeeding. Instead,
children born to T cruzi-infected mothers should be tested during infancy and
treated if necessary. Unfortunately, prenatal screening recommendations are not
widely followed, even in endemic countries. Many at-risk infants are born to
mothers with unknown Tcruzi status. Pediatricians should consider testing these
newborns forTcruzi, especially if they are symptomatic. Diagnostic testing should
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adults. Cure rates of nearly 100%are observed in congenitally
infected infants who receive treatment within the first post-
natal year. The cure rate decreases to approximately 60% in
older children with chronic infections. Prompt detection and
treatment of congenital T cruzi infection is, therefore, essen-
tial to avoid future complications.
COMMENT: I found this In Brief fascinating because I
have not been familiar with the presentation of Chagas
disease nor considered it in the differential diagnosis of
patients. Yet, the World Health Organization estimates that
Chagas disease is the most prevalent parasitic disease in the
American continents, including North, Central, and South
America.
As the authors noted, the presentation in newborns is
diverse, making diagnosis challenging for those who are not
familiar with the wide range of possibilities. Congenital
Chagas disease must be considered in infants born to moth-
ers who are from endemic areas, such as the southern portion
of South America: Brazil, Paraguay, Argentina, and Bolivia.
Early identification and treatment can prevent progression to
more serious manifestations associated with chronic infec-
tion. Chronic Chagas disease can affect the heart, leading to
cardiomyopathy, associated arrhythmias, and cardiac dys-
function. Although less common, gastrointestinal involve-
ment can affect the esophagus or colon and lead to motility
disorders. Because treatment is available and effective,
diagnosis in both congenital and chronic states is impor-
tant to patient quality of life and prevention of resultant
morbidity.
– Janet Serwint, MD
Associate Editor, In Brief
be offered to siblings of any child diagnosed with Chagas 
disease, and the mother should also be referred for treat-
ment evaluation.
Newborns at risk for T cruzi infection should be tested 
with polymerase chain reaction (PCR), the preferred diagnos-
tic technique in children younger than age 9 months. PCR is 
more sensitive than microscopy-based techniques to detect 
Tcruzi  in blood, although it may not be available in resource-
limited areas. If the initial test result is negative, PCR should 
be repeated at 4 to 6 weeks of age because parasitemia may 
increase over the first postnatal month. Infants who lack 
detectable parasitemia should undergo serologic testing after 
age 9 months to confirm the absence of infection. Serologic 
methods such as enzyme-linked immunosorbent assay 
(ELISA) and immunofluorescent antibody test (IFA) should 
not be used in children younger than 9 months, in whom 
circulating maternal antibodies can cause false-positive 
results. After 9 months of age, serology becomes the diag-
nostic method of choice because parasitic DNA is often 
undetectable by PCR during the chronic stage of infection. 
Positive serology should be confirmed with a second assay 
because these tests have imperfect sensitivity and specificity.
All children diagnosed with T cruzi infection should 
receive antitrypanosomal therapy with either benznidazole 
or nifurtimox. Although these medications are not approved 
by the US Food and Drug Administration (FDA) in the 
United States, they can be obtained from the Centers for 
Disease Control and Prevention under investigational per-
mits. Standard therapy is a 60- to 90-day course of benzni-
dazole 5 to 7 mg/kg per day or nifurtimox 10 to 15 mg/kg per 
day divided in 2 to 3 daily doses. Both drugs have a high rate 
of adverse effects but are tolerated better in children than
